WO2007105984A1 - Agent à activité antimicrobienne - Google Patents

Agent à activité antimicrobienne Download PDF

Info

Publication number
WO2007105984A1
WO2007105984A1 PCT/RU2007/000025 RU2007000025W WO2007105984A1 WO 2007105984 A1 WO2007105984 A1 WO 2007105984A1 RU 2007000025 W RU2007000025 W RU 2007000025W WO 2007105984 A1 WO2007105984 A1 WO 2007105984A1
Authority
WO
WIPO (PCT)
Prior art keywords
iodine
suppository
drug
antimicrobial
suppositories
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2007/000025
Other languages
English (en)
Russian (ru)
Inventor
Lev Davidovich Rasnetsov
Iakov Yudelevitch Shvartsman
Irina Konstantinovna Lyalina
Original Assignee
Zakrytoe Aktsionernoe Obschest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zakrytoe Aktsionernoe Obschest filed Critical Zakrytoe Aktsionernoe Obschest
Priority to EEP200800057A priority Critical patent/EE200800057A/xx
Publication of WO2007105984A1 publication Critical patent/WO2007105984A1/fr
Anticipated expiration legal-status Critical
Priority to LVP-08-170A priority patent/LV13887B/lv
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the invention relates to the pharmaceutical industry, in particular to the creation of an antimicrobial agent in the form of suppositories containing iodine, and can be used in clinical practice in the treatment of inflammatory diseases of the female genital area.
  • an antimicrobial agent in the form of suppositories containing iodine
  • SUBSTITUTE SHEET (RULE 26)
  • the "alternative" way of drug delivery allows not only to increase the effectiveness of treatment, but also to avoid many adverse effects of taking the drug.
  • the genitourinary system is known to be difficult to access for most drugs; to create the necessary concentrations of drugs in the focus of inflammation often increase the dose.
  • Iodine is a well-known antiseptic. Iodine is widely used in medical practice for inflammatory and other diseases of the skin and mucous membranes, however, the use of iodine to create drugs is limited by its solubility. For external use, usually 5-10% iodine solutions are used. For the treatment of gynecological diseases, 20 mg per suppository is enough.
  • Known drug "Betadine" - vaginal suppositories.
  • the active substance - iodine is in the form of a complex with polyvinylpyrrolidone (povidone). 1 suppository contains 200 mg of iodine-povidone and 2.8 g of macrogol. The concentration of active iodine is 0.1-1%. (The Register of Russian Medicines - Radar, 2003, p.236)
  • the drug is a broad spectrum antiseptic against bacteria, viruses, fungi and protozoa.
  • SUBSTITUTE SHEET (RULE 26) - mixed infections (infections caused by Gardperella vagipalis, fungi, trichomonads).
  • the drug can be used as a prophylactic before surgical operations in the vagina or diagnostic procedures.
  • vaginal suppository In acute vaginitis, 1 vaginal suppository is prescribed 2 times a day for 7 days. For subacute and chronic vaginitis, 1 suppository per day is prescribed for 14 days. If necessary, the course of treatment can be extended.
  • Yodoksid vaginal suppositories.
  • 1 suppository contains 0.2 g of iodine-povidone and a base (polyethylene oxide 1500 and polyethylene oxide-400) up to 3 g (P LS, 2003, p. 489).
  • Known drugs have side effects - they cause itching, flushing at the place of use and allergic reactions. In addition, it is not recommended to use polyethylene oxides on the mucous membranes.
  • Refusal of treatment is often caused by intolerance to drugs containing iodine.
  • the objective of the present invention is to expand the arsenal of antimicrobial agents for the treatment of gynecological diseases.
  • the technical result of the invention lies in the fact that the claimed tool does not have side effects when using it (itching, hyperemia and allergic reactions) due to
  • SUBSTITUTE SHEET decrease in active iodine per suppository.
  • the active complex including iodine-DMSO (dimethyl sulfoxide)
  • iodine-DMSO dimethyl sulfoxide
  • the problem is solved as follows:
  • the proposed antimicrobial agent made in the form of a suppository, including the active substance iodine and excipient, characterized in that the active substance is made in the form of a complex iodine-DMSO (dimethyl sulfoxide) in the ratio l: (l-10), and as a filler, it contains a fat-soluble base, while the iodine content in the suppository is from 10 to 20 mg. In suppositories weighing Ir, the iodine content can be 10 mg.
  • the iodine content can be 10 mg.
  • the iodine content can be 20 mg.
  • the fat-soluble base may be cocoa butter or solid fat or witepsol.
  • the claimed tool is called "Bagitrite.”
  • Dimethyl sulfoxide belongs to the pharmacotherapeutic group - dermatotropic drugs.
  • the pharmacological action is anti-inflammatory.
  • SUBSTITUTE SHEET (RULE 26) (antiseptic) and fibrinolytic effect. It penetrates quickly and well through biological membranes, including through the skin and mucous membranes, and increases their permeability to other drugs. Changes the sensitivity of antibiotic-resistant microflora.
  • Iodine is readily soluble in DMSO at room temperature.
  • a solution of iodine in DMSO can be introduced into compositions with both fat-soluble bases and water-soluble ones.
  • the solution of iodine in DMSO when applied to tissues ensures the penetration of iodine through biological membranes, including through the mucous membranes without damaging the latter.
  • DMSO has a local anesthetic, local anti-inflammatory, antimicrobial effect.
  • the medicinal product “Bagitrite” is prepared as follows. Iodine in a ratio of 1: 1 is mixed with DMSO at room temperature until completely dissolved.
  • Vitepsol brand H-15 (ND 42-9583-98) and / or Vitepsol brand W-35 (ND 42-9584-98) or cocoa butter or any solid fat for suppository base is melted at a temperature of 40-60 0 C.
  • the base is cooled to a temperature of 35-36 0 C and add a solution of iodine in DMSO so that the iodine content in the mixture does not exceed 1%.
  • the suppository mass is poured into a blister strip packaging with a volume of 1 or 2 cm 3 at a temperature of 35 ° C. Hermetically sealed. Cool at a temperature of 5-8 ° C. Get suppositories weighing 1 or 2 g, the deviation in mass within ⁇ 5%.
  • SUBSTITUTE SHEET (RULE 26) Appearance of the suppository: brown, hard, brittle on break, with a specific smell of iodine, torpedo-shaped.
  • the drug in the conditions of the test (dilution 1:10) has an antimicrobial effect.
  • the tests are carried out according to the Global Fund XI ed., Vol. 2 “Methods of microbiological control of medicines)) and Changes N ° 3 dated 06/19/2003.
  • the drug under the conditions of the microbiological purity test (dilution 1: 10) has an antimicrobial effect against Capsida albisaps, you. serus and Asr. piger.
  • Table 1 illustrates the antimicrobial effect of the drug “Baitreet-10 mg” weighing 1.0 g.
  • Table 2 illustrates the antimicrobial effect of the drug “Baitreet-10 mg” weighing 2.0 g.
  • Table 3 illustrates the quantitative assessment of the antimicrobial effect of the drug “Baitreet-10 mg)) in comparison with other antimicrobial and analog drugs containing iodine.
  • the drug BAGITRIT-10 mg vaginal suppositories weighing 1.0 g has an antimicrobial effect against Vasillus serus, Sapdida albicaps at a dilution of 1:50, and in relation to Asreggillus piger - 1:20.
  • the antimicrobial effect in relation to these test microorganisms is removed by dilution of the drug 1: 100.
  • Example 2 Evaluation of the antimicrobial effect of the drug “Bagitrite-10 mg” weighing 2.0 g.
  • the drug Bagitrite-10 mg vaginal suppositories weighing 2.0 g has an antimicrobial effect against Vasillus serus, Sapdida albicaps and Aspergillus piger at a dilution of 1:20.
  • the antimicrobial effect in relation to these test microorganisms is removed by dilution of the drug 1:50.
  • Example 3 A quantitative assessment of the antimicrobial effect of the drug "Bagitrite” in comparison with other antimicrobial drugs and analog preparations containing iodine.
  • SUBSTITUTE SHEET (RULE 26) the following concentrations of each drug ( ⁇ g / ml): 1000-100-10-1-0.1-0.01-Ki-K 2 . Each dilution of the preparations was examined in triplicate.
  • the minimum inhibitory concentration of “Bagitra” for all tested strains of microorganisms is 0.2-2.0 ⁇ g / ml, i.e. comparable to the effect of known antibiotics.
  • “Bagitrite” has a much wider spectrum of action, as it is able to suppress the vital activity of fungi (C.albisaps).
  • the new drug has a pronounced antimicrobial effect in concentrations comparable to effective doses of antibiotics. It has a wider spectrum of action compared to most antibiotics used in medical practice.
  • “Bagitrite” was used in complex therapy (cycloferon, El / phoresis, lidase, Mihomax) for vaginal debridement of 5 suppositories at night. Treatment showed that the tolerance of suppositories is good, suppositories are compatible in complex therapy. As a result, a smear of the II degree of purity while maintaining normoflora.
  • Example 5 Patient P. I. - diagnosis: nonspecific colpitis. Treatment only with candles “Bagitrite” (5 suppositories in the vagina at night). Tolerance is good.
  • Example 6 Patient V. O. -diagnosis: nonspecific colpitis, cervical erosion.
  • vagina was sanitized in front of the cervical erythrocytes of the uterus with only “Baitron”, 5 suppositories at night. Tolerance is good. Before treatment - the degree of purity of the smear is 3 to 4, after treatment - 2.
  • Example 7 Patient P. E. - the diagnosis of salpinitis, ureaplasmosis, chlamydia, adhesive process of the pelvis, bacterial vaginosis.
  • Example 8 Patient S. H. Diagnosis: 6 weeks pregnancy, nonspecific colpitis.
  • the vagina was sanitized with “Bacitra” (5 suppositories at night).
  • suppositories exhibit a wide range of antimicrobial effects and can be used for vaginal debridement with nonspecific colpitis, bacterial vaginosis, ureaplasmosis, etc.
  • suppositories can be used in the complex treatment of chlamydia, viral infection, in preoperative preparation for the treatment of cervical erosion, while suppositories do not cause side effects

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention relève de l'industrie chimique et pharmaceutique, se rapporte en particulier à la production d'un agent antimicrobien en ovule contenant de l'iode, et peut être utilisée dans la pratique clinique pour traiter des maladies inflammatoires de la région génitale féminine. L'agent antimicrobien selon l'invention, qui se présente sous la forme d'un ovule et contient un principe actif sous forme d'iode et un excipient, est caractérisé en ce que le principe actif est constitué d'un complexe iode-diméthylsulfoxyde (DMSO) présentant un rapport de 1:(1-10), et en ce que l'excipient est constitué d'une base liposoluble, la teneur en iode de l'ovule étant comprise entre 10 et 20 mg. Les ovules selon l'invention possèdent un large spectre antimicrobien.
PCT/RU2007/000025 2006-03-13 2007-01-24 Agent à activité antimicrobienne Ceased WO2007105984A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EEP200800057A EE200800057A (et) 2006-03-13 2007-01-24 Antimikroobne ravimvorm
LVP-08-170A LV13887B (lv) 2006-03-13 2008-10-07 Pretmikrobu līdzeklis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2006107864 2006-03-13
RU2006107864/15A RU2318523C2 (ru) 2006-03-13 2006-03-13 Средство антимикробного действия

Publications (1)

Publication Number Publication Date
WO2007105984A1 true WO2007105984A1 (fr) 2007-09-20

Family

ID=38509732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2007/000025 Ceased WO2007105984A1 (fr) 2006-03-13 2007-01-24 Agent à activité antimicrobienne

Country Status (8)

Country Link
EA (1) EA010981B1 (fr)
EE (1) EE200800057A (fr)
GE (1) GEP20115210B (fr)
LT (1) LT5570B (fr)
LV (1) LV13887B (fr)
RU (1) RU2318523C2 (fr)
UA (1) UA93234C2 (fr)
WO (1) WO2007105984A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
RU2470659C1 (ru) * 2011-09-09 2012-12-27 Сергей Андреевич Калиниченко Средство "ректофит 1"
RU2470660C1 (ru) * 2011-09-09 2012-12-27 Сергей Андреевич Калиниченко Средство "ректофит 2"
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
ITUA20162013A1 (it) 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017408A (en) * 1975-07-14 1977-04-12 Fults Elmer H Water soluble liquid iodine concentrate, aqueous iodine bacteriocidal solution and methods of making the same
RU2080864C1 (ru) * 1993-11-09 1997-06-10 Евгений Владимирович Намоконов Средство для лечения гнойных ран
RU2240780C1 (ru) * 2003-09-05 2004-11-27 Фаизов Тагир Хадиевич Бактерицидное и противовоспалительное средство в виде мази

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2115412C1 (ru) * 1997-04-22 1998-07-20 Открытое акционерное общество "Нижегородский химико-фармацевтический завод" Вагинальные суппозитории антибактериального действия

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017408A (en) * 1975-07-14 1977-04-12 Fults Elmer H Water soluble liquid iodine concentrate, aqueous iodine bacteriocidal solution and methods of making the same
RU2080864C1 (ru) * 1993-11-09 1997-06-10 Евгений Владимирович Намоконов Средство для лечения гнойных ран
RU2240780C1 (ru) * 2003-09-05 2004-11-27 Фаизов Тагир Хадиевич Бактерицидное и противовоспалительное средство в виде мази

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PJIC - APTEKAR, no. 5, 2003, pages 299, 402, 486, 489 *

Also Published As

Publication number Publication date
RU2006107864A (ru) 2007-09-20
LT2008067A (en) 2009-02-25
RU2318523C2 (ru) 2008-03-10
GEP20115210B (en) 2011-04-26
EA200700353A1 (ru) 2007-10-26
LV13887A (lv) 2009-03-20
EA010981B1 (ru) 2008-12-30
LV13887B (lv) 2009-08-20
UA93234C2 (ru) 2011-01-25
LT5570B (lt) 2009-05-25
EE200800057A (et) 2008-10-15

Similar Documents

Publication Publication Date Title
JP2893035B2 (ja) 増強された抗菌剤組成物
EA010981B1 (ru) Средство антимикробного действия
US7718642B2 (en) AIDS prophylactic lubricating composition
US20050238728A1 (en) Synergistic topically applied personal hygiene product
EP0772445B1 (fr) Compositions pharmaceutiques utilisables principalement comme ovule, renfermant plusieurs ingredients actifs differents
JP2009530316A (ja) 避妊用組成物
CN113082050A (zh) 一种妇科用温敏凝胶及其制备方法
Mohr et al. Actinomycosis treated with lincomycin
CN108404111A (zh) 一种以芸豆植物凝集素为主要成分的抑菌抗病毒制剂
RU2200570C1 (ru) Комплекс природных соединений растительного происхождения, обладающий сперматоцидным эффектом и активностью в отношении инфекций, передаваемых половым путем
ES2929646T3 (es) Aplicación de totarol y composición farmacéutica que contiene totarol
WO1997009988A1 (fr) Preparation biologiquement active contenant du vinylene, de l'ethonium et la decamethoxine
CN114306428A (zh) 一种妇科抗菌抗炎中药复方组合物及其应用
RU2200572C1 (ru) Комплекс природных соединений растительного происхождения, обладающий противоинфекционным действием в отношении инфекций, передаваемых половым путем
RU2657785C1 (ru) Композиция для интравагинального введения
ES2974996T3 (es) Preparación para el tratamiento y/o la profilaxis de enfermedades infecciosas inflamatorias
RU2229878C1 (ru) Спермицидная активность этония
Wilkins Surgical wound management in dogs using an improved stable chlorine dioxide antiseptic solution
RU2779613C2 (ru) Средство для приготовления противомикробного лечебного раствора (варианты), способ организации средства для приготовления противомикробного лечебного раствора (варианты)
RU2166314C2 (ru) Лечебно-профилактическое средство "гексикон", обладающее антибактериальным и антисептическим действием
DE102010032590B4 (de) Arzneimittel zur lokalen Behandlung der Wundinfektion
CN102600192A (zh) 一种治疗皮肤病的复方特比萘芬纳米药物及其制备方法
RU2123854C1 (ru) Средство для лечения инфекционных заболеваний дыхательных путей
Kumari et al. A Case Series on Lodra Vata Kashaya Yoni Praskhalana in Shweta Pradara wsr to vaginal infections due to Staphylococcus aures
RU2172179C2 (ru) Шарики "биосан" для лечения кольпитов различного генеза и способ лечения кольпитов различного генеза

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07716009

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: LT2008067

Country of ref document: LT

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008 20080170

Country of ref document: LV

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10932

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 2008067

Country of ref document: LT

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 07716009

Country of ref document: EP

Kind code of ref document: A1